clinical trial · NCT06596694
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 180
Gastrointestinal CancerPatritumab deruxtecan
brief summary
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
started
Nov 3, 2024
primary completion
Dec 7, 2028
completion
Dec 7, 2028
last updated
Jun 1, 2026
official title
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol